Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression.

ABSTRACT:

Background

The early growth response 1 (EGR1) is a central transcription factor involved in systemic sclerosis (SSc) pathogenesis. Iguratimod is a synthesized anti-rheumatic disease-modifying drug, which shows drastic inhibition to EGR1 expression in B cells. This study is aiming to investigate the anti-fibrotic effect of iguratimod in SSc.

Methods

EGR1 was detected by immunofluorescence staining real-time PCR or western blot. Iguratimod was applied in EGR1 overexpressed or knockdown human dermal fibroblast, bleomycin pre-treated mice, tight skin 1 mice, and SSc skin xenografts. RNA sequencing was performed in cultured fibroblast and xenografts to identify the iguratimod regulated genes.

Results

EGR1 overexpressed predominantly in non-immune cells of SSc patients. Igu

SUBMITTER: Shen L 

PROVIDER: S-EPMC10439582 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature